Executive Team


James Hoyes

Chief Executive Officer

Delivering new options to patients to better help manage their health and wellness provides the drive behind the day-to-day efforts of the Alitair team. By executing our business plan crisply – on time, on budget – and with the level of quality required for success with regulators and clinicians, Alitair can significantly improve both stakeholder and shareholder value.

Mr. Hoyes began supporting Alitair Pharmaceuticals in late 2016 and was appointed Chief Executive Officer in March 2017. He was also appointed to the Board of Directors in April 2017.

Mr. Hoyes has over 30 years of experience in biopharmaceuticals working on both in industry and in healthcare strategic consulting. He has a proven track record of building high performing teams and delivering consistent year-over-year double-digit revenue growth. Mr. Hoyes has deep experience in building brands, therapeutic areas and companies. He began his career at Sterling Winthrop in sales and earned positions of increasing responsibility in sales management, marketing,strategic marketing and managed care. Mr. Hoyes’s experiences at Sanofi (acquirer of Sterling Winthrop) included work with the launches of Avapro and Plavix and culminated with a position as Vice President, Managed Care. He then joined Elan as Vice President, Marketing which encompassed Neurology, Primary Care and Hospital brands. Mr. Hoyes then joined Serono in 2004 and quickly assumed positions of increasing seniority as EVP, Neurology Therapeutic Area and Chief Commercial Officer. His final position at EMD Serono (US division of Merck Serono) was President and Head of US Operations. This position was the lead of a US organization of over 1,000 employees and gross revenues approaching $2 billion.

Presently, Mr. Hoyes is also an Executive Partner with RxC International, a premier healthcare strategy consulting group. Beginning in mid-2018, Mr. Hoyes was engaged by ENDECE as a Strategic Advisor to the CEO. In addition to this extensive experience in therapeutic area leadership and general management, Mr. Hoyes has served on the boards of PhRMA, BIO (Health Section Governing Board), MassBIO as well as several charitable organizations.


Helmut H. Albrecht, MD, MS. FFPM

Our focus on innovative formulation technology and orphan drug developments to address critical unmet medical needs is a key element of Alitair’s mission and what drives us to excel and meet the company’s objectives and goals.

Chief Scientific Officer

Dr. Albrecht is a 20 year veteran of the pharmaceutical business and brings a wealth of product development experience to the Company. Most recently, Dr. Albrecht was head of R&D at Adams Respiratory Therapeutics where he managed a wide variety of R&D, clinical and medical projects in cough, COPD and allergy. He was also a member of the senior management group at Adams, Business Operations Team (BOT). Prior to joining Adams Respiratory, he was VP of Global Clinical & Medical Development at Novartis Consumer Health. Earlier in his career he held key positions in the areas of pharmaceutical medicine, the Rx & OTC drug development space, the support of dietary supplement products at SmithKline Beecham, Procter & Gamble, and Altana Pharma in Germany and the US.


Frank Guarino

Senior Vice President, Finance

Frank was the Chief Operating Officer of Millennium Biotechnlogies, Inc. from July 2010 through August, 2014 and previously served as its Chief Financial Officer since 2001. Frank has been engaged in consulting projects in the financial services industry for the past several years. Mr. Guarino has a Bachelor of Science degree in Accounting from St. Peter’s University.


Frank Koos

Senior Vice President, Business Development

Koos has over 20 years of pharmaceutical experience serving in positions of increasing responsibility to include Vice President of Professional Sales at Adams Respiratory Therapeutics from 2003-2009 where he was chosen to stay on at Reckitt Benckiser in the same role post sale of Adams to Reckitt. He was also a key member of the business development due diligence team at Adams. During his tenure he lead the professional sales team to help grow revenue from the launch of Mucinex from a zero base to almost $500m in sales. From 2009-2010, Koos served as the Senior Vice President of Sales, Marketing, and Business Development for MiddleBrook Pharmaceuticals, which launched the first FDA-approved once-daily amoxicillin. Post MiddleBrook, Koos served as the Head of Sales and Marketing for Healthy Advice where he lead post merger and rebranding initiatives of newly acquired PatientPoint into a fully integrated digital marketing point of care pharma marketing services organization. From 2013 to present, Koos serves as executive partner for RxC International, a life sciences management consulting firm focusing on corp strategy, product development, and commercialization. RxC serves both start-up and world leading pharma/biotech companies.


Joseph Tomasek

General Counsel

Mr. Tomasek has represented private and public entities in corporate and securities law matters, including mergers, acquisitions, private and public securities offerings, regulatory and administrative projects and transactions for over 35 years. He received his Juris Doctor degree and Bachelor of Arts degree in History from Seton Hall University as well as a Certificate d’Etude in Common Market Studies from the University of Strasbourg, France.


William W. Howard, Ph.D., MBA


William W. Howard, Ph.D., MBA, is  serving as President of Alitair. He is also the Founder, Chairman of the Board of Directors. Prior to starting the Company, Dr. Howard served as Senior Vice President of New Products and Business Development for Adams Respiratory Therapeutics, which is best known for the highly successful Mucinex® cough/cold product line. Adams was acquired by Reckitt Benckiser in January 2008 for $2.3 billion, nearly 7 times its fiscal 2007 sales. Dr. Howard first worked for Adams as a consultant in 2001 and later joined Adams in 2004 as a full-time employee after working on the initial commercialization strategy for Mucinex®. After Adams was acquired by global consumer goods powerhouse Reckitt Benckiser in 2008, Dr. Howard applied the lessons he learned, which culminated in founding Alitair and developing a strategy to develop a portfolio of products for the prescription market.


Russell F. Somma, Ph.D

R&D Consultant

Dr. Somma is a pharmaceutical industry veteran with over 30 years of product development experience, primarily at Ciba-Geigy/Novartis. He has considerable experience working with the FDA, having been involved in the development, manufacturing and approval of over 25 NDAs. It is anticipated that Dr. Somma’s expertise and background will greatly advantage Alitair’s research & development programs.